Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for ACP-204 in Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
8/2/23- Completed Ph1 development. 11/27/23- Ph2 trial initiated. 11/07/24- Ongoing development. 11/05/25:- PR No update. 05/06/26:- Reaffirmed expectation for Phase 2 remlifanserin Alzheimer's psychosis topline data between August and October 2026. 07/20/26:- RADIANT Ph2 enrollment completed; topline expected September To October 2026; Phase 3 screening and enrollment underway; Fast Track granted. 08/04/26:- RADIANT Ph2 topline remains expected September To October 2026; Ph3 screening continues.
Verification
Confirm timing and program details against the company announcement or filing.